DUBLIN--(BUSINESS WIRE)--The "Global Opioid Induced Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.
The opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 - 2025.
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs market growth. The global opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 - 2025.
North America is the dominant regional OIC drugs market through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs market in North America. On the other hand, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global OIC Drugs Market Analysis
Chapter 4 Global OIC Drugs Market, by Drug Type
Chapter 5 Global OIC Drugs Market, by Prescription Type
Chapter 6 Global OIC Drugs Market, by Geography
Chapter 7 Company Profiles
- Astrazenenca
- Shionogo & Co Ltd
- Salix Pharmaceuticals Ltd
- Synergy Pharmaceuticals Inc
- Cubist Pharmaceuticals (Adolor Corporation) - A Subsidiary Of Merck
- Sucampo Pharmaceuticals
- Ironwood Pharmaceuticals, Inc.
- Daiichi Sankyo Co. Ltd.
- Pfizer
- Progenics Pharmaceuticals Inc
For more information about this report visit https://www.researchandmarkets.com/research/3x8wzz/global_opioid
